View Clinical Trial (Medical Research Study)

Effectiveness of Cognitive Behavioral Therapy for Treating Depression in People With Bipolar I Disorder - NCT00595387-02114(Clinical Trial 198499)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Boston
State:  
MA
Zip Code: 02114
Conditions: Bipolar Disorder - Depression
Purpose: This study will compare the effectiveness of cognitive behavioral therapy versus supportive psychotherapy in decreasing depression in people with bipolar disorder.
Study summary: Bipolar I disorder (BP-I) is a chronic debilitating disorder with recurrent depressive and/or manic mood episodes. Although episodes of mania are often considered the most distinguishing feature of bipolar disorder, recurrent episodes of depression make up the most functionally debilitating aspect for many individuals with BP-I. Symptoms of depressive episodes include depressed mood, lack of interest, decreased energy, low self-esteem, trouble sleeping, and change in appetite. Mood stabilizers are usually the first line of treatment for patients with bipolar disorder who are in a depressive episode, but previous research has shown that these treatments fail to bring most patients to sustained remission. As an adjunct to medication, a psychosocial treatment known as cognitive behavioral therapy (CBT) may be a promising treatment for improving depressive symptoms and for long-term stabilization in individuals with BP-I. This study will compare the effectiveness of CBT versus supportive psychotherapy in decreasing depression in people with BP-I. Using magnetic resonance imaging (MRI), this study will also assess the impact of episodic memory impairment in people with BP-I on the success of CBT treatment. Participation in this single-blind study will last about 9 months and will include 22 study visits. There will be four pretreatment visits, during which participants will undergo a variety of tests and procedures, including interviews and questionnaires about depression and anxiety; tests on memory, attention, reaction time, and reading; and an MRI scan. Following completion of the initial assessments, participants will be randomly assigned to receive CBT or supportive psychotherapy. Participants in both groups will attend eighteen 1-hour treatment sessions over 5 months. Participants attending CBT sessions will learn specific thought processing and behavioral exercises to help reduce depressive symptoms. Participants attending psychosocial therapy sessions will learn about signs and symptoms related to depression and will be provided support in coping with their depression. All participants will be asked to complete Mood and Memory Questionnaires before and after the first seven treatment sessions. Psychological evaluations will occur after Visits 8 and 18 of treatment and will involve the completion of questionnaires. Participants in both groups will attend a follow-up visit to evaluate tic symptoms, anxiety, and mood 4 months after the final treatment session.
Criteria: Inclusion Criteria: - Normal or corrected-to-normal vision (tested by vision charts) - Diagnosis of bipolar I disorder by the Mini International Neuropsychiatric Interview (MINI) - HAM-D score of 17 or higher Exclusion Criteria: - Meets criteria for DSM-IV bipolar I disorder subtype rapid cycling - Meets criteria for DSM-IV mixed episode - Pregnant - Serious medical illness - Neurologic disorder and/or head trauma - Current or past history of selected DSM-IV Axis I disorders other than bipolar disorder, including organic mental disorder, schizophrenia, delusional disorder, and psychotic disorders not otherwise specified - Substance abuse or dependence within the 12 months prior to study entry and/or history of substance abuse for more than 12 months - IQ of less than 80 on the Wechsler Adult Reading Test - Previous treatment with CBT for depression - Contraindications to MRI (e.g., metallic implants, claustrophobia)
Study is available at: Massachusetts General Hospital Bipolar Clinic and Research Program
Boston, MA 02114
United States

Primary Contact:
Rebecca M. Ametrano, BA
Email: rametrano@partners.org
Phone: 617-724-6545
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.